Cancer name Colon Cancer
Cancer Type COCA
Immunotherapy type Adoptive Cell Therapy
Treatment γδT cells
Drugstatus NA
Drugbank ID NA
Checkpoints NA
Signature Type Protein
Signature granzyme B
Official Symbol GZMB
Mode of action PROT_D_UP
Description for ‘mode of action’:the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation),Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental mouse model
Description Treating γδT cells with 0.5μM, 1.0μM and 2μM of TWS119 increased the expression level of granzyme B in a dose-dependent manner. Whilst,4.0μM and 8.0μM of TWS119 did not affect the expression level ofgranzyme B compared with the control group .
PMID 29104081
Title Wnt pathway activator TWS123 enhances the proliferation and cytolytic activity of human γδT cells against colon cancer